Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IMVT 1402

Next Previous
X
Search
Drug Profile

IMVT 1402

Alternative Names: HL-161-ANS; IMVT-1402

Latest Information Update: 06 Jan 2025

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator HanAll Biopharma
  • Developer HanAll Biopharma; Roivant Sciences
  • Class Monoclonal antibodies
  • Mechanism of Action Neonatal Fc receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Graves' disease
  • Phase I Autoimmune disorders

Most Recent Events

  • 17 Dec 2024 Phase-II clinical trials in Graves' disease (In adults, In the elderly) in USA (SC) (NCT06727604)
  • 11 Dec 2024 Immunovant Sciences plans a phase II trial for Graves' disease in unknown location (SC) (NCT06727604)
  • 07 Nov 2024 Regulatory bodies approves IND application for IMVT 1402 in various indications including Rheumatoid arthritis

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top